Peter J. Rossi, MD, discusses innovations and advances in lowdoserate (LDR) and highdoserate (HDR) prostate brachytherapy as well as American Brachytherapy Society (ABS) initiatives and training opportunities. Dr. Rossi explains that innovations have resulted in brachytherapy treatment that is evidencebased, innovative, efficient, costeffective, flexible, yields highly personalized treatment, and is of high value to multidisciplinary teams and to patients.